Rosiglitazone: Potential beneficial impact on cardiovascular disease

International Journal of Clinical Practice

Volumn 57, Issue 2, 2003, Pages 128-134

  Viberti, G C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; C REACTIVE PROTEIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRIC ACID DERIVATIVE; GELATINASE B; GLIBENCLAMIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR; ORAL ANTIDIABETIC AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PLASMINOGEN ACTIVATOR INHIBITOR 1; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TROGLITAZONE;

ATHEROSCLEROSIS; BODY WEIGHT DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DYSLIPIDEMIA; EDEMA; FLUID RETENTION; HEART PROTECTION; HUMAN; HYPERGLYCEMIA; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIVER DYSFUNCTION; LIVER TOXICITY; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RAT; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SIDE EFFECT; WEIGHT GAIN;

ALBUMINURIA; ARTERIOSCLEROSIS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; HUMANS; HYPERGLYCEMIA; HYPERLIPIDEMIAS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; OBESITY; RISK FACTORS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0037347859     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (90)

1. World Health Organization/International Diabetes Federation. The economics of diabetes and diabetes care: a report of the Diabetes Health Economics Study Group. Geneva: WHO, 1999.
2. Viberti G. Prognostic significance of microalbuminuria. Am J Hypertens 1994; 7: 69S-72S.
3. Rubin RR, Peyrot M. Quality of life and diabetes. Diabetes Metab Res Rev 1999; 15: 205-218.
4. Redekop WK, Koopmanschap MA, Stolk RP et al. Health-related quality of life and treatment satisfaction in Dutch patients with type 2 diabetes. Diabetes Care 2002; 25: 458-463.
5. Selby JV, Ray GT, Zhang D et al. Excess costs of medical care for patients with diabetes in a managed care population. Diabetes Care 1997; 20: 1396-1402.
6. Glauber H, Brown J. Impact of cardiovascular disease on health care utilization in a defined diabetic population. J Clin Epidemiol 1994; 47: 1133-1142.
7. Currie CJ, Morgan CL, Peters JR. Patterns and costs of hospital care for coronary heart disease related and not related to diabetes. Heart 1997; 78: 544-549.
8. O'Brien JA, Shomphe LA, Kavanagh PL et al. Direct medical costs of complications resulting from type 2 diabetes in the US. Diabetes Care 1998; 21: 1122-1128.
9. Brown JB, Pedula KL, Bakst AW. The progressive cost of complications in type 2 diabetes mellitus. Arch Intern Med 1999; 159: 1873-1880.
10. Nichols GA, Brown JB. The impact of cardiovascular disease on medical care costs in subjects with and without type 2 diabetes. Diabetes Care 2002; 25: 482-486.
11. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21: 1414-1431.
12. Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001; 414: 782-787.
13. Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-1607.
14. Haffner SM, Valdez RA, Hazuda HP et al. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715-722.
15. Reasner CA. Promising new approaches. Diabetes Obes Metab 1999; 1(suppl 1): S41-S48.
16. Lebovitz HE, Banerji MA. Insulin resistance and its treatment by thiazolidinediones. Recent Prog Horm Res 2001; 56: 265-294.
17. Goldstein BJ. Rosiglitazone. Int J Clin Pract 2000; 54: 333-337.
18. Bonora E, Kiechl S, Willeit J et al. Prevalence of insulin resistance in metabolic disorders: the Bruneck Study. Diabetes 1998; 47: 1643-1649.
19. Bjorntorp P. Abdominal obesity and the metabolic syndrome. Ann Med 1992; 24: 465-468.
20. Reaven GM. Role of insulin resistance in human disease (syndrome X): an expanded definition. Ann Rev Med 1993; 44: 121-131.
21. Groop L, Ekstrand A, Forsblom C et al. Insulin resistance, hypertension and microalbuminuria in patients with type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1993; 36: 642-647.
22. Mykkanen L, Zaccaro DJ, Wagenknecht LE et al. Microalbuminuria is associated with insulin resistance in nondiabetic subjects: the insulin resistance atherosclerosis study. Diabetes 1998; 47: 793-800.
23. Juhan-Vague I, Thompson SG, Jespersen J. Involvement of the hemostatic system in the insulin resistance syndrome: a study of 1500 patients with angina pectoris. ECAT Angina Pectoris Study Group. Arterioscler Thromb 1993; 13: 1865-1873.
24. Festa A, D'Agostino R, Howard G et al. Chronic subclinical inflammation as part of the insulin resistance syndrome: the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2000; 102: 42-47.
25. World Health Organization. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: Diagnosis and classification of diabetes mellitus. Geneva: WHO Department of Noncommunicable Disease Surveillance, 1999.
26. Isomaa B, Almgren P, Tuomi T et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.
27. Isomaa B, Henricsson M, Almgren P et al. The metabolic syndrome influences the risk of chronic complications in patients with type II diabetes. Diabetologia 2001; 44: 1148-1154.
28. Minamikawa J, Tanaka S, Yamauchi M et al. Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 1998; 83: 1818-1820.
29. Inzucchi SE, Maggs DG, Spollett GR et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867-872.
30. Yu JG, Kruszynska YT, Mulford MI et al. A comparison of troglitazone and metformin on insulin requirements in euglycemic intensively insulin-treated type 2 diabetic patients. Diabetes 1999; 48: 2414-2421.
31. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
32. Chu NV, Kong AP, Kim DD et al. Differential effects of metformin and troglitazone, on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25: 542-549.
33. Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998; 47: 507-514.
34. Dubois M, Pattou F, Kerr-Conte J et al. Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in normal human pancreatic islet cells. Diabetologia 2000; 43: 1165-1169.
35. Plutzky J. Peroxisome proliferator-activated receptors in endothelial cell biology. Curr Opin Lipidol 2001; 12: 511-518.
36. Reginato MJ, Lazar MA. Mechanisms by which thiazolidinediones enhance insulin action. Trends Endocrinol Metab 1999; 10: 9-13.
37. Mayerson AB, Hundal RS, Dufour S et al. The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 2002; 51: 797-802.
38. Carey DG, Cowin GJ, Galloway GJ et al. Sensitivity effect of rosiglitazone on insulin and body composition in type 2 diabetic patients. Obes Res 2002; 10: 1008-1015.
39. Miyazaki Y, Glass L, Triplitt C et al. Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type II diabetic patients. Diabetologia 2001; 44: 2210-2219.
40. Lebovitz HE, Dole JF, Patwardhan R et al. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. J Clin Endocrinol Metab 2001; 86: 280-288.
41. Wolffenbuttel BH, Gomis R, Squatrito S et al. Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in type 2 diabetic patients. Diabet Med 2000; 17: 40-47.
42. Matthews DR, Bakst AW, Weston WM et al. Rosiglitazone decreases insulin resistance and improves beta-cell function in patients with type 2 diabetes. Diabetologia 1999; 42(suppl 1): A228.
43. Deacon L, Donnelly S, Stewart M. Rosiglitazone is effective in obese and non-obese patients with type 2 diabetes. Diabetes 2001; 50(suppl 2): A433.
44. Bennett SMA, Jones NP, Agrawal A et al. Rosiglitazone improves insulin sensitivity and 24-hour ambulatory blood pressure in subjects with IGT. Diabetologia 2001; 44(suppl 1): A200.
45. Raji A, Seely EW, Bekins SAR et al. Improved insulin sensitivity and reduced blood pressure after rosiglitazone treatment in non-diabetic hypertensive patients. Diabetes 2002; 51(suppl 2): A355.
46. Jones NP, Mather R, Owen S et al. Long-term efficacy of rosiglitazone as monotherapy or in combination with metformin. Diabetologia 2000; 43(suppl 1): A192.
47. Phillips LS, Grunberger G, Miller E et al. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Rosiglitazone Clinical Trials Study Group. Diabetes Care 2001; 24: 308-315.
48. Raskin P, Rappaport EB, Cole ST et al. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with type II diabetes. Diabetologia 2000; 43: 278-284.
49. Nolan JJ, Jones NP, Patwardhan R et al. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus. Diabet Med 2000; 17: 287-294.
50. Patel J, Anderson RJ, Rappaport EB. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Diabetes Obes Metab 1999; 1: 165-172.
51. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA 2000; 283: 1695-1702.
52. Viberti G, Kahn SE, Greene DA et al. A Diabetes Outcome Progression Trial (ADOPT): an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 2002; 25: 1737-1743.
53. Viberti G, Mogensen CE, Groop LC et al. Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group. JAMA 1994; 271: 275-279.
54. Ravid M, Savin H, Jutrin I et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118: 577-581.
55. Bakris G, Viberti G, Weston W et al. Rosiglitazone reduces urinary albumin excretion in type 2 diabetes. J Hum Hypertens. In press.
56. Betteridge DJ. Diabetic dyslipidaemia. Eur J Clin Invest 1999; 29: 12-16.
57. Laakso M, Voutilainen E, Pyorala K et al. Association of low HDL and HDL2 cholesterol with coronary heart disease in noninsulin-dependent diabetics. Arteriosclerosis 1985; 5: 653-658.
58. American Diabetes Association. Management of dyslipidemia in adults with diabetes. Diabetes Care 2002; 25(suppl 1): S74-S77.
59. European Diabetes Policy Group. A desktop guide to type 2 diabetes. Diabet Med 1999; 16: 716-730.
60. National Institutes of Health. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel III). Publication No. 01-3670: 2001.
61. British Cardiac Society, British Hyperlipidaemia Association, British Hypertension Society, endorsed by the British Diabetic Association. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 1998; 80(suppl 2): S1-29.
62. Cheng-Lai A, Levine A. Rosiglitazone: an agent from the thiazolidine-dione class for the treatment of type 2 diabetes. Heart Dis 2000; 2: 326-333.
63. Brunzell J, Cohen BR, Kreider M et al. Rosiglitazone favorably affects LDL-C and HDL-C heterogeneity in type 2 diabetes. Diabetes 2001; 50(suppl 2): A141.
64. Cobitz A, Hand L, Gould E et al. Rosiglitazone increases HDL cholesterol levels in patients with type 2 diabetes mellitus. Abstract. Drugs Affecting Lipid Metabolism Meeting, New York, USA, September 2001.
65. Freed MI, Ratner R, Marcovina SM et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol 2002; 90: 947-952.
66. American Diabetes Association. Treatment of hypertension in adults with diabetes. Diabetes Care 2002; 25: 199-201.
67. Kelley DE, McKolanis TM, Kelley CA. Comparative effects of rosiglitazone and metformin on fatty liver and visceral adiposity in type 2 diabetes mellitus. Diabetes 2002; 51(suppl 2): A35.
68. Virtanen KA, Hällsten K, Parkkola R et al. Different effects of rosiglitazone and metformin on adipose tissue glucose uptake in type 2 diabetes. Diabetes 2002; 51(suppl 2): A145.
69. Banerji M, Lebovitz HE, Dugbartey M. Rosiglitazone selectively increases subcutaneous but not visceral adipose tissue mass in type 2 diabetes mellitus. Diabetes 2001; 50(suppl 2): A90.
70. Mykkanen L, Zaccaro DJ, O'Leary DH et al. Microalbuminuria and carotid artery intima-media thickness in nondiabetic and NIDDM subjects. Insulin Resistance Atherosclerosis Study (IRAS). Stroke 1997; 28: 1710-1716.
71. Goff DC Jr, D'Agostino RB Jr, Haffner SM et al. Lipoprotein concentrations and carotid atherosclerosis by diabetes status: results from the Insulin Resistance Atherosclerosis Study. Diabetes Care 2000; 23: 1006-1011.
72. Haffner SM, D'Agostino RJ, Mykkanen L et al. Insulin sensitivity in subjects with type 2 diabetes: relationship to cardiovascular risk factors. Insulin Resistance Atherosclerosis Study. Diabetes Care 1999; 22: 562-568.
73. Yue TT, Chen J, Bao W et al. In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 2001; 104: 2588-2594.
74. Sidell RJ, Cole MA, Draper NJ et al. Thiazolidinedione treatment normalizes insulin resistance and ischemic injury in the Zucker fatty rat heart. Diabetes 2002; 51: 1110-1117.
75. Khandoudi N, Delerive P, Berrebi-Bertrand I et al. Rosiglitazone, a peroxisome proliferator-activated receptor-gamma, inhibits the Jun NH(2)-terminal kinase/activating protein 1 pathway and protects the heart from ischemia/reperfusion injury. Diabetes 2002; 51: 1507-1514.
76. Haffner S, Greenberg AS, Weston WM et al. Effect of rosiglitazone treatment on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus. Circulation 2002; 106: 679-684.
77. Mohanty P, Aljada A, Ghanim H et al. Evidence for a potent anti-inflammatory effect of rosiglitazone in obese diabetes patients. Diabetes 2002; 51(suppl 2): A109.
78. Ikeda U, Matsui K, Murakami Y et al. Monocyte chemoattractant protein-1 and coronary artery disease. Clin Cardiol 2002; 25: 143-147.
79. Yang WS, Jeng CY, Wu TJ et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002; 25: 376-380.
80. Freed M, Fuell D, Menci L et al. Effect of combination therapy with rosiglitazone and glibenclamide on PAI-1 antigen, PAI-1 activity and tPA in patients with type 2 diabetes. Diabetologia 2000; 43(suppl 1): A267.
81. Agrawal A, Chen H, Yan Y et al. Rosiglitazone improves postprandial glycemia and markers of endothelial function in patients with type 2 diabetes. Diabetes 2002; 51(suppl 2): A92.
82. Koenig W, Sund M, Frohlich M et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg cohort study, 198. Circulation 1999; 99: 237-242.
83. Juhan-Vague I, Alessi MC, Morange PE. Hypofibrinolysis and increased PAI-1 are linked to atherothrombosis via insulin resistance and obesity. Ann Med 2000; 32(suppl 1): 78-84.
84. Stuhlinger MC, Abbasi F, Chu JW et al. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002; 287: 1420-1426.
85. Plummer EV, Lawson M, Domb A et al. Effects of treatment with rosiglitazone on myocardial blood flow (MBF) in type 2 diabetes (DM2). Diabetes 2002; 51(suppl 2): A161.
86. Natali A, Baldeweg S, Toschi E et al. Rosiglitazone directly improves endothelial function in type 2 diabetic patients. Diabetes 2002; 51(suppl 2): A142.
87. Parulkar AA, Pendergrass ML, Granda-Ayala R et al. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med 2001; 134: 61-71.
88. King AB. A comparison in a clinical setting of the efficacy and side effects of three thiazolidinediones. Diabetes Care 2000; 23: 557.
89. Lebovitz HE, Kreider M, Freed MI. Evaluation of liver function in type 2 diabetic patients during clinical trials: evidence that rosiglitazone does not cause hepatic dysfunction. Diabetes Care 2002; 25: 815-821.
90. Home P, Gubb J. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of glycaemia in Diabetes (RECORD): a long-term cardiovascular outcome study. Diabetes 2002; 51(suppl 2): A487.